Financial News
Kirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors
The law firm of Kirby McInerney LLP is investigating potential claims against Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA). The investigation concerns whether Verrica has violated the federal securities laws and/or engaged in other unlawful business practices.
Verrica is a dermatology therapeutics company that develops and commercializes treatments for people with skin diseases in the United States.
On May 24, 2022, after the market closed, Verrica announced that the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter regarding its New Drug Application for molluscum contagiosum treatment, VP-102. Specifically, the FDA cited “deficiencies identified at a general reinspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica’s bulk solution drug product.” On this news, the price of Verrica shares declined by $3.55 per share, or approximately 63.8%, from $5.56 per share to close at $2.01 per share on May 25, 2022.
If you purchased or otherwise acquired Verrica securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005403/en/
Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-371-6600
https://www.kmllp.com
investigations@kmllp.com
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.